Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 27
Filter
1.
Circ Res ; 133(4): 313-329, 2023 08 04.
Article in English | MEDLINE | ID: mdl-37449401

ABSTRACT

BACKGROUND: ZFHX3 (zinc finger homeobox 3), a gene that encodes a large transcription factor, is at the second-most significantly associated locus with atrial fibrillation (AF), but its function in the heart is unknown. This study aims to identify causative genetic variation related to AF at the ZFHX3 locus and examine the impact of Zfhx3 loss on cardiac function in mice. METHODS: CRISPR-Cas9 genome editing, chromatin immunoprecipitation, and luciferase assays in pluripotent stem cell-derived cardiomyocytes were used to identify causative genetic variation related to AF at the ZFHX3 locus. Cardiac function was assessed by echocardiography, magnetic resonance imaging, electrophysiology studies, calcium imaging, and RNA sequencing in mice with heterozygous and homozygous cardiomyocyte-restricted Zfhx3 loss (Zfhx3 Het and knockout, respectively). Human cardiac single-nucleus ATAC (assay for transposase-accessible chromatin)-sequencing data was analyzed to determine which genes in atrial cardiomyocytes are directly regulated by ZFHX3. RESULTS: We found single-nucleotide polymorphism (SNP) rs12931021 modulates an enhancer regulating ZFHX3 expression, and the AF risk allele is associated with decreased ZFHX3 transcription. We observed a gene-dose response in AF susceptibility with Zfhx3 knockout mice having higher incidence, frequency, and burden of AF than Zfhx3 Het and wild-type mice, with alterations in conduction velocity, atrial action potential duration, calcium handling and the development of atrial enlargement and thrombus, and dilated cardiomyopathy. Zfhx3 loss results in atrial-specific differential effects on genes and signaling pathways involved in cardiac pathophysiology and AF. CONCLUSIONS: Our findings implicate ZFHX3 as the causative gene at the 16q22 locus for AF, and cardiac abnormalities caused by loss of cardiac Zfhx3 are due to atrial-specific dysregulation of pathways involved in AF susceptibility. Together, these data reveal a novel and important role for Zfhx3 in the control of cardiac genes and signaling pathways essential for normal atrial function.


Subject(s)
Atrial Fibrillation , Homeodomain Proteins , Animals , Humans , Mice , Atrial Fibrillation/genetics , Calcium/metabolism , Dilatation , Homeodomain Proteins/genetics , Homeodomain Proteins/metabolism , Myocytes, Cardiac/metabolism , Transcription Factors/genetics
3.
JACC Clin Electrophysiol ; 9(5): 680-685, 2023 05.
Article in English | MEDLINE | ID: mdl-36752474

ABSTRACT

Intramural ventricular arrhythmias are challenging to treat. Adjunctive techniques such as bipolar ablation, ethanol injection, use of a needle catheter, or surgery have been described. These are often not readily available. This is a case report of a patient with refractory intramural ventricular arrhythmia that was ablated by incorporating electrodes of a mapping catheter into the ablation circuit. The results of ex vivo experiments to determine the characteristics of multipolar ablation lesions using different ablation settings are reported. The feasibility of generating transmural lesions with multipolar ablation in vivo in a porcine model was tested.


Subject(s)
Catheter Ablation , Tachycardia, Ventricular , Animals , Swine , Arrhythmias, Cardiac/surgery , Electrodes , Ethanol , Catheter Ablation/methods
6.
JACC Case Rep ; 4(4): 192-197, 2022 Feb 16.
Article in English | MEDLINE | ID: mdl-35199015

ABSTRACT

Potential foci for atrial tachycardia have been previously described in various locations including crista terminalis, tricuspid annulus, coronary sinus ostium, pulmonary vein ostia. In this report, we present a case of a focal atrial tachycardia arising from the posterior wall of the left atrium which has not been described before. (Level of Difficulty: Advanced.).

8.
Pacing Clin Electrophysiol ; 44(5): 895-902, 2021 May.
Article in English | MEDLINE | ID: mdl-33675073

ABSTRACT

BACKGROUND: There are limited data on the comparative analyses of TightRail rotating dilator sheath (Philips) and laser sheath for lead extraction. OBJECTIVE: To evaluate the effectiveness and safety of the TightRail sheath as a primary or secondary tool for transvenous lead extraction (TLE). METHODS: Retrospective cohort analysis of 202 consecutive patients who underwent TLE using either TightRail sheath and/or GlideLight laser sheath (Philips) in our hospital. The study population was divided into three groups: Group A underwent TLE with laser sheath only (N = 157), Group B with TightRail sheath only (N = 22), and Group C with both sheaths (N = 23). RESULTS: During this period, 375 leads in 202 patients were extracted, including 297 leads extracted by laser sheath alone, 45 leads by TightRail sheath alone, and 33 by both TightRail sheath and laser sheaths. The most common indications included device infection (44.6%) and lead-related complications (44.1%). The median age of leads was 8.9 years. TightRail sheath (Group B) achieved similar efficacy as a primary extraction tool compared with laser sheath (Group A), with complete procedure success rate of 93.3% (vs. 96.6%, P = .263) and clinical success rate of 100.0% (vs. 98.1%, P = .513). Among 32 leads in which Tightrail was used after laser had failed (Group C), the complete procedure success rate was 75.8%. No significant difference in procedural adverse events was observed. CONCLUSION: Our single-center experience confirms that the TightRail system is an effective first-line and second-line method for TLE. Further investigation is required to guide the selection of mechanical and laser sheaths in lead extraction cases.


Subject(s)
Device Removal/instrumentation , Electrodes, Implanted , Defibrillators, Implantable , Equipment Design , Female , Humans , Lasers , Male , Middle Aged , Pacemaker, Artificial , Retrospective Studies
9.
Heliyon ; 6(11): e05465, 2020 Nov.
Article in English | MEDLINE | ID: mdl-33235937

ABSTRACT

Solidifiers are dry, granular hydrophobic polymers that form physical bonds with hydrocarbons by molecular interactions (hydrogen bonding, London forces), and are used to immobilize hydrocarbon spill propagation and dispersion. CIAgent© is a non-toxic, proprietary polymer blend listed as an "Oil Solidifier" on the EPA's National Contingency Plan Product Schedule for use on hydrocarbon spills in the navigable waterways of United States. CIAgent solidifies the liquid hydrocarbons through a rapid transformation into a cohesive rubber-like inert mass upon contact and retains the liquid for easier removal and disposal. The objective of this paper is to determine the effectiveness of the solidifier with a variety of hydrocarbon liquids that could be encountered in an oil spill scenario. The effectiveness of the solidifier was characterized in terms of the application rate, temperature change, solubility parameters and solidification time for a variety of hydrocarbon liquids (e. g., gasoline, diesel fuel, crude oil) that could be encountered by measuring the heat of solidification using a solution calorimeter. A thermogram was obtained and the heat of solidification was calculated using the temperature difference upon solidification. The temperature change and the degree of swelling in the solidifier were used to determine the solubility parameter of the solidifier (6.77 Hildebrands). The heat of solidification value was used to determine the ease and speed of the solidification of the hydrocarbon liquids. Solidification times ranged from 40 to 120 s for the liquids tested. The average application ratio in weight of solidifier to weight of hydrocarbon ranged was 3.35.

10.
Circulation ; 142(25): 2443-2455, 2020 12 22.
Article in English | MEDLINE | ID: mdl-33092403

ABSTRACT

BACKGROUND: Ibrutinib is a Bruton tyrosine kinase inhibitor with remarkable efficacy against B-cell cancers. Ibrutinib also increases the risk of atrial fibrillation (AF), which remains poorly understood. METHODS: We performed electrophysiology studies on mice treated with ibrutinib to assess inducibility of AF. Chemoproteomic analysis of cardiac lysates identified candidate ibrutinib targets, which were further evaluated in genetic mouse models and additional pharmacological experiments. The pharmacovigilance database, VigiBase, was queried to determine whether drug inhibition of an identified candidate kinase was associated with increased reporting of AF. RESULTS: We demonstrate that treatment of mice with ibrutinib for 4 weeks results in inducible AF, left atrial enlargement, myocardial fibrosis, and inflammation. This effect was reproduced in mice lacking Bruton tyrosine kinase, but not in mice treated with 4 weeks of acalabrutinib, a more specific Bruton tyrosine kinase inhibitor, demonstrating that AF is an off-target side effect. Chemoproteomic profiling identified a short list of candidate kinases that was narrowed by additional experimentation leaving CSK (C-terminal Src kinase) as the strongest candidate for ibrutinib-induced AF. Cardiac-specific Csk knockout in mice led to increased AF, left atrial enlargement, fibrosis, and inflammation, phenocopying ibrutinib treatment. Disproportionality analyses in VigiBase confirmed increased reporting of AF associated with kinase inhibitors blocking Csk versus non-Csk inhibitors, with a reporting odds ratio of 8.0 (95% CI, 7.3-8.7; P<0.0001). CONCLUSIONS: These data identify Csk inhibition as the mechanism through which ibrutinib leads to AF. Registration: URL: https://ww.clinicaltrials.gov; Unique identifier: NCT03530215.


Subject(s)
Adenine/analogs & derivatives , Antineoplastic Agents/toxicity , Atrial Fibrillation/chemically induced , Atrial Function, Left/drug effects , CSK Tyrosine-Protein Kinase/antagonists & inhibitors , Heart Atria/drug effects , Heart Rate/drug effects , Piperidines/toxicity , Protein Kinase Inhibitors/toxicity , Action Potentials/drug effects , Adenine/toxicity , Agammaglobulinaemia Tyrosine Kinase/deficiency , Agammaglobulinaemia Tyrosine Kinase/genetics , Animals , Atrial Fibrillation/enzymology , Atrial Fibrillation/physiopathology , CSK Tyrosine-Protein Kinase/genetics , CSK Tyrosine-Protein Kinase/metabolism , Databases, Genetic , Heart Atria/enzymology , Heart Atria/physiopathology , Humans , Mice, 129 Strain , Mice, Inbred C57BL , Mice, Inbred CBA , Mice, Knockout , Risk Assessment , Risk Factors
11.
J Cardiovasc Electrophysiol ; 31(5): 1083-1090, 2020 05.
Article in English | MEDLINE | ID: mdl-32128930

ABSTRACT

BACKGROUND: Interrupted inferior vena cava (IVC) is a rare venous anomaly that complicates the treatment of patients who require electrophysiology (EP) procedures. METHODS: We describe five consecutive cases of patients with interrupted IVC who presented to the EP laboratory requiring interventional procedures including catheter ablation for atrial fibrillation and supraventricular tachycardia and left atrial appendage closure. All cases were successfully completed utilizing a variety of approaches to vascular access including transseptal puncture via transhepatic and internal jugular approaches. CONCLUSION: Procedures in the EP lab can be performed successfully in patients with interrupted IVC.


Subject(s)
Arrhythmias, Cardiac/therapy , Atrial Appendage , Cardiac Catheterization , Catheter Ablation , Heart Conduction System/surgery , Pulmonary Veins/surgery , Vena Cava, Inferior/abnormalities , Action Potentials , Adult , Aged, 80 and over , Arrhythmias, Cardiac/diagnostic imaging , Arrhythmias, Cardiac/physiopathology , Atrial Appendage/diagnostic imaging , Atrial Appendage/physiopathology , Cardiac Catheterization/adverse effects , Cardiac Catheterization/instrumentation , Catheter Ablation/adverse effects , Female , Heart Conduction System/physiopathology , Heart Rate , Humans , Male , Pulmonary Veins/physiopathology , Treatment Outcome , Vena Cava, Inferior/diagnostic imaging
12.
Card Electrophysiol Clin ; 11(1): 155-164, 2019 03.
Article in English | MEDLINE | ID: mdl-30717848

ABSTRACT

Several clinical trials have established the role of cardiac resynchronization therapy in patients with heart failure, impaired left ventricular function and dyssynchrony. Challenges to traditional therapy include coronary sinus anatomy and failure to respond. Left ventricular endocardial pacing could overcome anatomic constraints, provide more flexibility, and allow for more physiologic activation. Cases and case series have demonstrated the promise of the approach. Preclinical studies support the superior hemodynamic effects of left ventricular endocardial pacing. Leadless left ventricular endocardial pacing is a recent innovation that is undergoing prospective testing. Successful delivery may be associated with clinical response and positive cardiac structural remodeling.


Subject(s)
Cardiac Resynchronization Therapy , Heart Failure/therapy , Cardiac Resynchronization Therapy Devices , Heart Ventricles/surgery , Humans , Prospective Studies
13.
Circ Genom Precis Med ; 11(5): e002037, 2018 05.
Article in English | MEDLINE | ID: mdl-29748316

ABSTRACT

BACKGROUND: Electrical conduction from the cardiac sinoatrial node to the ventricles is critical for normal heart function. Genome-wide association studies have identified more than a dozen common genetic loci that are associated with PR interval. However, it is unclear whether rare and low-frequency variants also contribute to PR interval heritability. METHODS: We performed large-scale meta-analyses of the PR interval that included 83 367 participants of European ancestry and 9436 of African ancestry. We examined both common and rare variants associated with the PR interval. RESULTS: We identified 31 genetic loci that were significantly associated with PR interval after Bonferroni correction (P<1.2×10-6), including 11 novel loci that have not been reported previously. Many of these loci are involved in heart morphogenesis. In gene-based analysis, we found that multiple rare variants at MYH6 (P=5.9×10-11) and SCN5A (P=1.1×10-7) were associated with PR interval. SCN5A locus also was implicated in the common variant analysis, whereas MYH6 was a novel locus. CONCLUSIONS: We identified common variants at 11 novel loci and rare variants within 2 gene regions that were significantly associated with PR interval. Our findings provide novel insights to the current understanding of atrioventricular conduction, which is critical for cardiac activity and an important determinant of health.


Subject(s)
Electrocardiography , Genetic Variation , Adult , Aged , Female , Genome-Wide Association Study , Humans , Male , Middle Aged , Quantitative Trait Loci/genetics , Regulatory Sequences, Nucleic Acid/genetics
14.
Appl Physiol Nutr Metab ; 42(10): 1023-1030, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28591543

ABSTRACT

Stress is associated with increased susceptibility to infection. We investigated if the mechanism involves immunomodulation of dendritic cells and whether this can be inhibited by a polyphenol-rich diet. Blood samples were taken from a total of 100 male endurance athletes at 5 time points around a marathon run: 4 weeks before; 1 week before; and immediately, 24 h, and 72 h after. Participants were randomized into 2 double-blinded groups. One group received a polyphenol-rich beverage during a 3-week training phase before marathon while the other group received a placebo beverage. Flow cytometric analysis of dendritic cell (DC) counts and subpopulation counts (myeloid, plasmocytoid DCs) was performed. Levels of viral antigen presenting toll-like receptor (TLR) 7 messenger RNA was measured by real-time polymerase chain reaction. Marathon running induced a significant increase of circulating myeloid DCs (0.2% vs. 0.33% of whole-blood leukocytes (wbl); p < 0.01) and a significant decrease of plasmozytoid DCs (0.12% vs. 0.03% of wbl; p < 0.01) and TLR7 expression (decline of 60%; p < 0.01). Polyphenol supplementation did not significantly affect mobilization of dendritic cells but showed beneficial effects on regeneration of TLR7 expression in wbl at 3 days postmarathon (decline of 40% vs. increase of 1000%; p < 0.05). In conclusion, physical stress affects circulating DCs, with an increase of myeloid and a decrease of plasmozytoid DCs. This may partially explain the susceptibility to viral infections after strenuous exercise. These detrimental effects are not attenuated by polyphenol supplementation. However, polyphenols support regeneration of viral antigen presenting TLR7 after strenuous exercise.


Subject(s)
Athletes , Dendritic Cells/drug effects , Diet , Exercise , Immunologic Factors/administration & dosage , Immunomodulation/drug effects , Physical Endurance/immunology , Polyphenols/administration & dosage , Administration, Oral , Adult , Beverages , Dendritic Cells/immunology , Dendritic Cells/metabolism , Double-Blind Method , Germany , Humans , Male , Middle Aged , Phenotype , Time Factors , Toll-Like Receptor 7/immunology , Toll-Like Receptor 7/metabolism , Treatment Outcome , Virus Diseases/immunology , Virus Diseases/prevention & control , Virus Diseases/virology , Young Adult
15.
Cell ; 169(3): 510-522.e20, 2017 04 20.
Article in English | MEDLINE | ID: mdl-28431249

ABSTRACT

Organ-specific functions of tissue-resident macrophages in the steady-state heart are unknown. Here, we show that cardiac macrophages facilitate electrical conduction through the distal atrioventricular node, where conducting cells densely intersperse with elongated macrophages expressing connexin 43. When coupled to spontaneously beating cardiomyocytes via connexin-43-containing gap junctions, cardiac macrophages have a negative resting membrane potential and depolarize in synchrony with cardiomyocytes. Conversely, macrophages render the resting membrane potential of cardiomyocytes more positive and, according to computational modeling, accelerate their repolarization. Photostimulation of channelrhodopsin-2-expressing macrophages improves atrioventricular conduction, whereas conditional deletion of connexin 43 in macrophages and congenital lack of macrophages delay atrioventricular conduction. In the Cd11bDTR mouse, macrophage ablation induces progressive atrioventricular block. These observations implicate macrophages in normal and aberrant cardiac conduction.


Subject(s)
Heart Conduction System , Macrophages/physiology , Animals , Connexin 43/metabolism , Female , Heart Atria/cytology , Humans , Male , Mice , Mice, Inbred C57BL , Middle Aged , Myocytes, Cardiac/physiology
16.
J Am Coll Cardiol ; 69(16): 2088-2095, 2017 Apr 25.
Article in English | MEDLINE | ID: mdl-28427583

ABSTRACT

Atrial fibrillation (AF) is an all-too-common and often challenging reality of clinical care. AF leads to significant morbidity and mortality; however, currently available treatments for AF have modest efficacy and high recurrence rates. In recent years, genetic therapy approaches have been explored in preclinical models of AF, and offer potential as a treatment modality with targeted delivery, tissue specificity, and therapy tailored to address mechanisms underlying the arrhythmia. However, many challenges remain before gene therapy can advance to a clinically relevant AF treatment. In this review, we summarize the available published data on gene therapy and discuss the challenges, opportunities, and limitations of this approach.


Subject(s)
Atrial Fibrillation/therapy , Genetic Therapy , Atrial Fibrillation/etiology , Humans
17.
Appl Physiol Nutr Metab ; 42(5): 523-528, 2017 May.
Article in English | MEDLINE | ID: mdl-28177719

ABSTRACT

Both physiologic stress and chronic heart disease are associated with increased systemic levels of chromogranin A (CGA) and NT-proBNP. Marathon running causes physiological stress and imposes a significant cardiac burden. Polyphenol-rich Mediterranean and Asian diets have been demonstrated to exert beneficial effects on the cardiovascular system. In this study we investigated whether pretreatment with a polyphenol beverage could attenuate the physiological and cardiac stress associated with a marathon. In the BeMaGIC trial, 277 athletes were randomized into 2 groups in a double-blinded fashion, receiving 1-1.5 L/day of the same beverages either with (study beverage) or without (placebo) polyphenol enrichment (approximately 400 mg of gallic acid equivalents per day of a complex mixture of polyphenols). Blood samples were taken 3 weeks and 1 day before, and immediately, 24 h, and 72 h after running a marathon. In our current substudy, CGA and NT-proBNP levels were analyzed by ELISA in the fastest 18 and the slowest 22 runners. CGA and NT-proBNP levels increased significantly immediately after the marathon and returned to baseline at 72 h after the marathon. Neither CGA nor NT-proBNP differed significantly between athletes receiving study beverage versus placebo. Separating our cohort into fast and slow runners did not reveal any significant difference regarding CGA or NT-proBNP levels between groups. Our study provides no evidence that polyphenol supplementation attenuates marathon running-induced physiological stress and cardiac burden in fast or slow runners.


Subject(s)
Heart/drug effects , Heart/physiology , Physical Endurance/drug effects , Polyphenols/pharmacology , Running , Stress, Physiological/drug effects , Adult , Beverages , Biomarkers/blood , Humans , Male , Middle Aged , Physical Endurance/physiology , Polyphenols/administration & dosage , Young Adult
18.
Heart Rhythm ; 14(2): 284-291, 2017 02.
Article in English | MEDLINE | ID: mdl-27756709

ABSTRACT

BACKGROUND: The genetic basis of atrial fibrillation (AF) and congenital heart disease remains incompletely understood. OBJECTIVE: We sought to determine the causative mutation in a family with AF, atrial septal defects, and ventricular septal defects. METHODS: We evaluated a pedigree with 16 family members, 1 with an atrial septal defect, 1 with a ventricular septal defect, and 3 with AF; we performed whole exome sequencing in 3 affected family members. Given that early-onset AF was prominent in the family, we then screened individuals with early-onset AF, defined as an age of onset <66 years, for mutations in GATA6. Variants were functionally characterized using reporter assays in a mammalian cell line. RESULTS: Exome sequencing in 3 affected individuals identified a conserved mutation, R585L, in the transcription factor gene GATA6. In the Massachusetts General Hospital Atrial Fibrillation (MGH AF) Study, the mean age of AF onset was 47.1 ± 10.9 years; 79% of the participants were men; and there was no evidence of structural heart disease. We identified 3 GATA6 variants (P91S, A177T, and A543G). Using wild-type and mutant GATA6 constructs driving atrial natriuretic peptide promoter reporter, we found that 3 of the 4 variants had a marked upregulation of luciferase activity (R585L: 4.1-fold, P < .0001; P91S: 2.5-fold, P = .0002; A177T; 1.7-fold, P = .03). In addition, when co-overexpressed with GATA4 and MEF2C, GATA6 variants exhibited upregulation of the alpha myosin heavy chain and atrial natriuretic peptide reporter activity. CONCLUSION: Overall, we found gain-of-function mutations in GATA6 in both a family with early-onset AF and atrioventricular septal defects as well as in a family with sporadic, early-onset AF.


Subject(s)
Atrial Fibrillation , Exome Sequencing , GATA6 Transcription Factor/genetics , Heart Septal Defects, Atrial , Heart Septal Defects, Ventricular , Adult , Age of Onset , Atrial Fibrillation/diagnosis , Atrial Fibrillation/epidemiology , Atrial Fibrillation/genetics , Female , Heart Septal Defects, Atrial/diagnosis , Heart Septal Defects, Atrial/epidemiology , Heart Septal Defects, Atrial/genetics , Heart Septal Defects, Ventricular/diagnosis , Heart Septal Defects, Ventricular/epidemiology , Heart Septal Defects, Ventricular/genetics , Humans , Male , Massachusetts/epidemiology , Middle Aged , Mutation , Pedigree , Exome Sequencing/methods
19.
BMC Med Genet ; 17(1): 83, 2016 Nov 17.
Article in English | MEDLINE | ID: mdl-27855642

ABSTRACT

BACKGROUND: The genetic basis for dilated cardiomyopathy (DCM) can be difficult to determine, particularly in familial cases with complex phenotypes. Next generation sequencing may be useful in the management of such cases. METHODS: We report two large families with pleiotropic inherited cardiomyopathy. In addition to DCM, the phenotypes included atrial and ventricular septal defects, cardiac arrhythmia and sudden death. Probands underwent whole exome sequencing to identify potentially causative variants. RESULTS: Each whole exome sequence yielded over 18,000 variants. We identified distinct mutations affecting a common amino acid in NKX2.5. Segregation analysis of the families support the pathogenic role of these variants. CONCLUSION: Our study emphasizes the utility of next generation sequencing in identifying causative mutations in complex inherited cardiac disease. We also report a novel pathogenic NKX2.5 mutation.


Subject(s)
Amino Acids/genetics , Cardiomyopathy, Dilated/genetics , Homeobox Protein Nkx-2.5/genetics , Amino Acids/metabolism , Cardiomyopathy, Dilated/diagnostic imaging , Cardiomyopathy, Dilated/pathology , DNA/chemistry , DNA/isolation & purification , DNA/metabolism , DNA Mutational Analysis , Death, Sudden, Cardiac/etiology , Electrocardiography , Female , Genotype , High-Throughput Nucleotide Sequencing , Humans , Male , Pedigree , Phenotype , Polymorphism, Single Nucleotide
20.
PLoS One ; 11(2): e0148599, 2016.
Article in English | MEDLINE | ID: mdl-26859843

ABSTRACT

INTRODUCTION: Physical activity is beneficial for individual health, but endurance sport is associated with the development of arrhythmias like atrial fibrillation. The underlying mechanisms leading to this increased risk are still not fully understood. MicroRNAs are important mediators of proarrhythmogenic remodeling and have potential value as biomarkers in cardiovascular diseases. Therefore, the objective of our study was to determine the value of circulating microRNAs as potential biomarkers for atrial remodeling in marathon runners (miRathon study). METHODS: 30 marathon runners were recruited into our study and were divided into two age-matched groups depending on the training status: elite (ER, ≥55 km/week, n = 15) and non-elite runners (NER, ≤40 km/week, n = 15). All runners participated in a 10 week training program before the marathon. MiRNA plasma levels were measured at 4 time points: at baseline (V1), after a 10 week training period (V2), immediately after the marathon (V3) and 24h later (V4). Additionally, we obtained clinical data including serum chemistry and echocardiography at each time point. RESULTS: MiRNA plasma levels were similar in both groups over time with more pronounced changes in ER. After the marathon miR-30a plasma levels increased significantly in both groups. MiR-1 and miR-133a plasma levels also increased but showed significant changes in ER only. 24h after the marathon plasma levels returned to baseline. MiR-26a decreased significantly after the marathon in elite runners only and miR-29b showed a non-significant decrease over time in both groups. In ER miRNA plasma levels showed a significant correlation with LA diameter, in NER miRNA plasma levels did not correlate with echocardiographic parameters. CONCLUSION: MiRNAs were differentially expressed in the plasma of marathon runners with more pronounced changes in ER. Plasma levels in ER correlate with left atrial diameter suggesting that circulating miRNAs could potentially serve as biomarkers of atrial remodeling in athletes.


Subject(s)
Atrial Remodeling/genetics , Atrial Remodeling/physiology , MicroRNAs/blood , MicroRNAs/genetics , Running/physiology , Adult , Atrial Fibrillation/blood , Atrial Fibrillation/etiology , Atrial Fibrillation/genetics , Biomarkers/blood , Creatine Kinase, MB Form/blood , Echocardiography , Genetic Markers , Germany , Heart Ventricles/diagnostic imaging , Hemolysis , Humans , Male , Middle Aged , Physical Endurance/genetics , Physical Endurance/physiology , Time Factors , Troponin T/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...